Lyell Immunopharma, Inc.

For the period ended Jun 30, 2025. Filed Aug 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 12, 2025

LYEL$16.75+8.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Revenue	$8	$13	$15	$16
Operating expenses:
Research and development	34,857	40,261	78,304	83,435
General and administrative	9,786	12,256	23,832	25,750
Other operating loss (income), net	1,062	(976)	943	(2,066)
Impairment of long-lived assets	1,443	—	1,443	—
Total operating expenses	47,148	51,541	104,522	107,119
Loss from operations	(47,140)	(51,528)	(104,507)	(107,103)
Interest income, net	3,276	6,364	7,138	13,183
Other income (expense), net	1,180	(645)	2,490	445
Impairment of other investments	—	—	—	(13,001)
Total other income, net	4,456	5,719	9,628	627
Net loss	(42,684)	(45,809)	(94,879)	(106,476)
Other comprehensive loss:
Net unrealized (loss) gain on marketable securities	(101)	7	(234)	(303)
Comprehensive loss	$(42,785)	$(45,802)	$(95,113)	$(106,779)
Net loss per common share, basic and diluted1	$(2.89)	$(3.59)	$(6.42)	$(8.36)
Weighted-average shares used to compute net loss per common share, basic and diluted1	14,793	12,770	14,774	12,741

Amounts previously reported have been retroactively adjusted to reflect the 1-for-20 reverse stock split effected on May 30, 2025. See Note 2.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.